Algorae Pharmaceuticals (ASX:1AI) has appointed Troy Valentine as a Non-Executive Director, a move the company says will materially deepen its board capability in capital markets, life sciences governance and international listed-company leadership.
Valentine joins Algorae after more than eight years chairing Incannex through its evolution from an ASX-listed early-stage business to a Nasdaq-listed clinical-stage pharmaceutical company.
Under his leadership, Incannex completed a successful Phase 2 trial for its lead candidate, secured U.S. FDA Fast Track designation in December 2025, and raised in excess of A$220 million across Australian and U.S. capital markets.
Algorae framed the appointment as part of a broader program of board renewal intended to support the company’s dual strategy of commercial pharmaceutical supply through AlgoraeRx and AI-enabled drug discovery via its AlgoraeOS platform.
The company also noted Valentine’s experience with cross-border governance, clinical-stage oversight, and access to institutional capital markets, including re-domiciliation and compliance with SEC and Nasdaq requirements.
The appointment coincides with the resignation of director Brad Dilkes, effective 14 July 2026, and will be subject to shareholder election at the next Annual General Meeting in accordance with the company constitution and ASX Listing Rules.
Executive Chairman David Hainsworth said, “We sought a director who operates credibly with the kind of global partners Algorae increasingly deals with, the Tier-1 manufacturers we source from and our international counterparties. Troy has chaired a Nasdaq-listed pharmaceutical company through a US listing, capital raisings in excess of $220 million, and FDA Fast Track designation for its lead candidate. That is the standard of experience we want on the Board, and a clear statement of our intent to scale this business.”
